Seyed M Moghadas

List of Publications by Year
in descending order

91 papers	4,429 citations	249298 26 h-index	156644 58 g-index
106 all docs	106 docs citations	106 times ranked	7313 citing authors

#	Article	IF	Citations
1	Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study. The Lancet Regional Health Americas, 2022, 5, 100085.	1.5	30
2	COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA. The Lancet Regional Health Americas, 2022, 6, 100147.	1.5	16
3	Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic. JAMA Network Open, 2022, 5, e2142725.	2.8	38
4	Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study. Lancet Regional Health - Europe, The, 2022, 14, 100304.	3.0	20
5	Impact of non-pharmaceutical interventions and vaccination on COVID-19 outbreaks in Nunavut, Canada: a Canadian Immunization Research Network (CIRN) study. BMC Public Health, 2022, 22, .	1.2	4
6	Comparative analyses of eighteen rapid antigen tests and RT-PCR for COVID-19 quarantine and surveillance-based isolation. Communications Medicine, 2022, 2, .	1.9	13
7	Ten years of Pan-InfORM: modelling research for public health in Canada. AIMS Public Health, 2021, 8, 265-274.	1.1	1
8	The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clinical Infectious Diseases, 2021, 73, 2257-2264.	2.9	376
9	Optimal COVID-19 quarantine and testing strategies. Nature Communications, 2021, 12, 356.	5.8	164
10	Simulated Identification of Silent COVID-19 Infections Among Children and Estimated Future Infection Rates With Vaccination. JAMA Network Open, 2021, 4, e217097.	2.8	22
11	Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biology, 2021, 19, e3001211.	2.6	111
12	Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada. Vaccine, 2021, 39, 2360-2365.	1.7	30
13	Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. EClinicalMedicine, 2021, 35, 100865.	3.2	100
14	Rapid disappearance of influenza following the implementation of COVID-19 mitigation measures in Hamilton, Ontario. Canada Communicable Disease Report, 2021, 47, 202-208.	0.6	6
15	Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada. Preventive Medicine, 2021, 148, 106564.	1.6	40
16	Can the USA return to pre-COVID-19 normal by July 4?. Lancet Infectious Diseases, The, 2021, 21, 1073-1074.	4.6	12
17	Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	345
18	The Unrecognized Death Toll of COVID-19 in the United States. The Lancet Regional Health Americas, 2021, 1, 100033.	1.5	9

#	Article	IF	Citations
19	Population Immunity Against COVID-19 in the United States. Annals of Internal Medicine, 2021, 174, 1586-1591.	2.0	20
20	Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada. EClinicalMedicine, 2021, 41, 101141.	3.2	14
21	Routine saliva testing for the identification of silent coronavirus disease 2019 (COVID-19) in healthcare workers. Infection Control and Hospital Epidemiology, 2021, 42, 1189-1193.	1.0	20
22	Importance of non-pharmaceutical interventions in the COVID-19 vaccination era: A case study of the Seychelles. Journal of Global Health, 2021, 11, 03104.	1.2	11
23	Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas. Lancet Infectious Diseases, The, 2021, 21, 1493-1494.	4.6	16
24	The impact of mask-wearing and shelter-in-place on COVID-19 outbreaks in the United States. International Journal of Infectious Diseases, 2020, 101, 334-341.	1.5	48
25	Dynamics of HSV-2 infection with a therapeutic vaccine. Heliyon, 2020, 6, e04368.	1.4	1
26	Simulating the effect of school closure during COVID-19 outbreaks in Ontario, Canada. BMC Medicine, 2020, 18, 230.	2.3	52
27	Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States. Cmaj, 2020, 192, E666-E670.	0.9	65
28	The implications of silent transmission for the control of COVID-19 outbreaks. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17513-17515.	3.3	419
29	Effectiveness and cost-effectiveness of a Clostridium difficile vaccine candidate in a hospital setting. Vaccine, 2020, 38, 2585-2591.	1.7	4
30	Curbing the 2019 Samoa measles outbreak. Lancet Infectious Diseases, The, 2020, 20, 287-288.	4.6	4
31	Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7504-7509.	3.3	429
32	Projecting hospital utilization during the COVID-19 outbreaks in the United States. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9122-9126.	3.3	441
33	Projecting demand for critical care beds during COVID-19 outbreaks in Canada. Cmaj, 2020, 192, E489-E496.	0.9	132
34	Modelling Therapeutic Vaccines. , 2020, , 381-394.		0
35	Projecting influenza vaccine effectiveness: A simulation study. PLoS ONE, 2020, 15, e0241549.	1.1	2
36	Delay in booster schedule as a control parameter in vaccination dynamics. Journal of Mathematical Biology, 2019, 79, 2157-2182.	0.8	8

#	Article	IF	Citations
37	Clostridium difficile intervention timelines for diagnosis, isolation, and treatment. American Journal of Infection Control, 2019, 47, 1370-1374.	1.1	4
38	Risk of influenza infection with low vaccine effectiveness: the role of avoidance behaviour. Epidemiology and Infection, 2019, 147, e75.	1.0	9
39	Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas. Emerging Infectious Diseases, 2019, 25, 2191-2196.	2.0	3
40	Cost-effectiveness of a potential vaccine candidate for Haemophilus influenzae serotype â€˜aâ€™. Vaccine, 2018, 36, 1681-1688.	1.7	5
41	Global dynamics of an epidemiological model with age-of-infection dependent treatment rate. Ricerche Di Matematica, 2018, 67, 125-140.	0.6	0
42	Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada. Scientific Reports, 2018, 8, 6492.	1.6	2
43	Cost-effectiveness of a potential Zika vaccine candidate: a case study for Colombia. BMC Medicine, 2018, 16, 100.	2.3	10
44	Individual movements and contact patterns in a Canadian long-term care facility. AIMS Public Health, 2018, 5, 111-121.	1.1	16
45	Improving epidemic size prediction through stable reconstruction of disease parameters by reduced iteratively regularized Gaussâ€"Newton algorithm. Journal of Inverse and Ill-Posed Problems, 2017, 25, 653-667.	0.5	3
46	The Effect of Individual Movements and Interventions on the Spread of Influenza in Long-Term Care Facilities. Medical Decision Making, 2017, 37, 871-881.	1.2	24
47	Mathematical modeling of tuberculosis. Mathematical Population Studies, 2017, 24, 1-2.	0.8	2
48	Drug resistance in an age-of-infection model. Mathematical Population Studies, 2017, 24, 64-78.	0.8	3
49	Asymptomatic Transmission and the Dynamics of Zika Infection. Scientific Reports, 2017, 7, 5829.	1.6	47
50	Assessing the effect of patient screening and isolation on curtailing Clostridium difficile infection in hospital settings. BMC Infectious Diseases, 2017, 17, 384.	1.3	7
51	Strategies for halting the rise of multidrug resistant TB epidemics: assessing the effect of early case detection and isolation. International Health, 2017, 9, 80-90.	0.8	10
52	Disease Risk Assessment Using a Voronoi-Based Network Analysis of Genes and Variants Scores. Frontiers in Genetics, 2017, 8, 29.	1.1	0
53	Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b. BMC Public Health, 2017, 17, 705.	1.2	11
54	Population dynamics of epidemic and endemic states of drug-resistance emergence in infectious diseases. PeerJ, 2017, 5, e2817.	0.9	3

#	Article	IF	Citations
55	Toward Standardizing a Lexicon of Infectious Disease Modeling Terms. Frontiers in Public Health, 2016, 4, 213.	1.3	19
56	COMPARATIVE DYNAMICS OF MONOVALENT AND BIVALENT VACCINATION FOR IMMUNOLOGICALLY UNRELATED PATHOGENS. Journal of Biological Systems, 2016, 24, 91-115.	0.5	0
57	Dynamics of naturally acquired antibody against Haemophilus influenzae type a capsular polysaccharide in a Canadian Aboriginal population. Preventive Medicine Reports, 2016, 3, 145-150.	0.8	7
58	Can treatment increase the epidemic size?. Journal of Mathematical Biology, 2016, 72, 343-361.	0.8	16
59	Using Phenomenological Models to Characterize Transmissibility and Forecast Patterns and Final Burden of Zika Epidemics. PLOS Currents, 2016, 8, .	1.4	123
60	Modelling the impact of vaccination on curtailing Haemophilus influenzae serotype â€˜aâ€™. Journal of Theoretical Biology, 2015, 387, 101-110.	0.8	6
61	The Potential Impact of Vaccination on the Dynamics of Dengue Infections. Bulletin of Mathematical Biology, 2015, 77, 2212-2230.	0.9	16
62	The impact of geographical location of residence on disease outcomes among Canadian First Nations populations during the 2009 influenza A(H1N1) pandemic. Health and Place, 2014, 26, 53-59.	1.5	10
63	Developing model-based public health policy through knowledge translation: the need for a â€˜Communities of Practiceâ€™. Public Health, 2014, 128, 561-567.	1.4	20
64	A GENERAL FRAMEWORK FOR AGENT-BASED MODELLING WITH APPLICATIONS TO INFECTIOUS DISEASE DYNAMICS. , 2014, , .		6
65	Antiviral Strategies for Emerging Influenza Viruses in Remote Communities. PLoS ONE, 2014, 9, e89651.	1.1	6
66	Optimal Treatment Profile During an Influenza Epidemic. Differential Equations and Dynamical Systems, 2013, 21, 237-252.	0.5	7
67	Impact of viral drift on vaccination dynamics and patterns of seasonal influenza. BMC Infectious Diseases, 2013, 13, 589.	1.3	13
68	Influenza H3N2 variant viruses with pandemic potential: Preventing catastrophe in remote and isolated Canadian communities. Preventive Medicine, 2013, 57, 910-913.	1.6	11
69	Optimality of a time-dependent treatment profile during an epidemic. Journal of Biological Dynamics, 2013, 7, 133-147.	0.8	5
70	Age Distribution of Infection and Hospitalization Among Canadian First Nations Populations During the 2009 H1N1 Pandemic. American Journal of Public Health, 2013, 103, e39-e44.	1.5	14
71	Transmissibility of the 2009 H1N1 pandemic in remote and isolated Canadian communities: a modelling study. BMJ Open, 2012, 2, e001614.	0.8	16
72	The Impact of Demographic Variables on Disease Spread: Influenza in Remote Communities. Scientific Reports, 2011, 1, .	1.6	30

#	Article	IF	Citations
73	Canada in the face of the 2009 H1N1 pandemic. Influenza and Other Respiratory Viruses, 2011, 5, 83-88.	1.5	22
74	Variability in transmissibility of the 2009 H1N1 pandemic in Canadian communities. BMC Research Notes, 2011, 4, 537.	0.6	14
75	Emergence of Resistance in Influenza With Compensatory Mutations. Mathematical Population Studies, 2011, 18, 106-121.	0.8	9
76	Original Article: Highly conserved cross-reactive CD4+ T-cell HA-epitopes of seasonal and the 2009 pandemic influenza viruses. Influenza and Other Respiratory Viruses, 2010, 4, 249-258.	1.5	38
77	Strategies for the Use of Oseltamivir and Zanamivir during Pandemic Outbreaks. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, e28-e63.	0.7	11
78	Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza. Cmaj, 2010, 182, 131-136.	0.9	212
79	Post-exposure prophylaxis during pandemic outbreaks. BMC Medicine, 2009, 7, 73.	2.3	23
80	A comparative evaluation of modelling strategies for the effect of treatment and host interactions on the spread of drug resistance. Journal of Theoretical Biology, 2009, 259, 253-263.	0.8	11
81	Antiviral resistance during pandemic influenza: implications for stockpiling and drug use. BMC Infectious Diseases, 2009, 9, 8.	1.3	33
82	A Delay Differential Model for Pandemic Influenza with Antiviral Treatment. Bulletin of Mathematical Biology, 2008, 70, 382-397.	0.9	57
83	Management of drug resistance in the population: influenza as a case study. Proceedings of the Royal Society B: Biological Sciences, 2008, 275, 1163-1169.	1.2	26
84	Waning Herd Immunity: A Challenge for Eradication of Measles. Rocky Mountain Journal of Mathematics, 2008, 38, .	0.2	4
85	Population-Wide Emergence of Antiviral Resistance during Pandemic Influenza. PLoS ONE, 2008, 3, e1839.	1.1	69
86	Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proceedings of the Royal Society B: Biological Sciences, 2007, 274, 1675-1684.	1.2	75
87	The impact of prophylaxis of healthcare workers on influenza pandemic burden. Journal of the Royal Society Interface, 2007, 4, 727-734.	1.5	14
88	Modelling the effect of CSII on the control of glucose concentration in type 1 diabetes. Applied Mathematics and Computation, 2007, 187, 1476-1483.	1.4	6
89	Gaining insights into human viral diseases through mathematics. European Journal of Epidemiology, 2006, 21, 337-342.	2.5	10
90	Bifurcations of an epidemic model with non-linear incidence and infection-dependent removal rate. Mathematical Medicine and Biology, 2006, 23, 231-254.	0.8	27

#	ARTICLE	IF	CITATIONS
91	Could Condoms Stop the AIDS Epidemic?. Journal of Theoretical Medicine, 2003, 5, 171-181.	0.5	29